Sovereign Health Announces Three-Part Editorial Series on Opioid Addiction Implant Probhuphine
Sovereign Health announces the launch of a new three-part editorial series focused on Probhuphine, an opioid subdermal implant for the treatment of opioid addiction. The inaugural article in this series takes an in-depth look at the use of the implant to treat opioid dependency; this is followed by part two, taking a look at the Food and Drug Administration's (FDA) postponement on its decision to approve the implant. Amid the changing of the guard from the current Food and Drug...
View full press release